NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.09 -2.84 (-3.47%) GOLD FUTURES
2,316.00 +13.10 (+0.57%) DOW
37,932.46 +116.54 (+0.31%) Bitcoin GBP
45,638.09 -2,771.21 (-5.72%)
PolyPid Ltd. (PYPD)
| Previous close | 4.79 |
| Open | 5.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.00 - 5.09 |
| 52-week range | 3.57 - 13.23 |
| Volume | |
| Avg. volume | 3,178 |
| Market cap | 24.37M |
| Beta (5Y monthly) | 1.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.99 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.33 |
GlobeNewswirePolyPid to Participate in Citizens JMP Life Sciences Conference
PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024. Citizens JMP Life Sciences Conference PresentationDate: Monday, May 13, 2024Time:2:30 PM ET The PolyPid management team will participate in one-on-one investor meeting
- GlobeNewswire
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the 200th patient in its ongoing SHIELD II Phase
- GlobeNewswire
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operati
